Advertisement

HIV and Indolent Lymphoma

  • Nadia KhanEmail author
  • Dipesh Uprety
  • Jenny Seo
  • Mark Leick
Chapter

Abstract

The incidence of non-Hodgkin’s lymphoma (NHL) is at least 100 times higher in the human immunodeficiency virus (HIV)-infected population as compared with the general population. Approximately 3 % of HIV/AIDS patients develop NHL. Among them, the risk increases with older age, duration of infection, and with a history of AIDS-defining events. Data supporting a decline in NHL in the post-HAART era are inconsistent. A prolonged immunocompromised state, with reduced immune surveillance, and chronic antigen stimulation, in the setting of infection with HIV, are contributors to the pathogenesis of NHL. Studies suggest that there are increased p53 gene abnormalities in HIV-1-related NHL. In this chapter, we will focus on the indolent subset of NHL in the HIV-infected population. Of the AIDS-defining illnesses, there are two subtypes of aggressive NHL including Burkitt lymphoma and DLBCL, which are disproportionately more prevalent among HIV lymphoma subtypes. There is a contradistinction in the prevalence of indolent subtypes of NHL in the HIV population, with the incidence rates of these lymphomas being lower as compared with the indolent subtypes in the general population, as described in SEER database analysis of patients from 1992 to 2009, suggesting less of an association with HIV.

Keywords

Human Immunodeficiency Virus Chronic Lymphocytic Leukemia Follicular Lymphoma Malt Lymphoma Human Immunodeficiency Virus Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Patel P, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med. 2008;148:728–36.CrossRefPubMedGoogle Scholar
  2. 2.
    Biggar RJ, Curtis RE, Cote TR, Rabkin CS, Melbye M. Risk of other cancers following Kaposi’s sarcoma: relation to acquired immunodeficiency syndrome. Am J Epidemiol. 1994;139:362–8.PubMedGoogle Scholar
  3. 3.
    Beral V, Peterman T, Berkelman R, Jaffe H. AIDS-associated non-Hodgkin lymphoma. Lancet (London, England). 1991;337:805–9.CrossRefGoogle Scholar
  4. 4.
    Biggar RJ, Rabkin CS. The epidemiology of AIDS – related neoplasms. Hematol Oncol Clin North Am. 1996;10:997–1010.CrossRefPubMedGoogle Scholar
  5. 5.
    Buchbinder SP, et al. Combination antiretroviral therapy and incidence of AIDS-related malignancies. J Acquir Immune Defic Syndr. 1999;21 Suppl 1:S23–6.PubMedGoogle Scholar
  6. 6.
    Rabkin CS, Testa MA, Huang J, Von Roenn JH. Kaposi’s sarcoma and non-Hodgkin’s lymphoma incidence trends in AIDS Clinical Trial Group study participants. J Acquir Immune Defic Syndr. 1999;21 Suppl 1:S31–3.PubMedGoogle Scholar
  7. 7.
    Jacobson LP, et al. Impact of potent antiretroviral therapy on the incidence of Kaposi’s sarcoma and non-Hodgkin’s lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 1999;21 Suppl 1:S34–41.PubMedGoogle Scholar
  8. 8.
    De Re V, et al. p53 protein over-expression and p53 gene abnormalities in HIV-1-related non-Hodgkin’s lymphomas. Int J Cancer J Int Cancer. 1994;56:662–7.CrossRefGoogle Scholar
  9. 9.
    Shiels MS, et al. The epidemic of non-Hodgkin lymphoma in the United States: disentangling the effect of HIV, 1992–2009. Cancer Epidemiol Biomark Prev: Publ Am Assoc Cancer Res Am Soc Prev Oncol. 2013;22:1069–78.CrossRefGoogle Scholar
  10. 10.
    Cote TR, et al. Non-Hodgkin’s lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer J Int Cancer. 1997;73:645–50.CrossRefGoogle Scholar
  11. 11.
    Biggar RJ, Rosenberg PS, Cote T. Kaposi’s sarcoma and non-Hodgkin’s lymphoma following the diagnosis of AIDS. Multistate AIDS/Cancer Match Study Group. Int J Cancer J Int Cancer. 1996;68:754–8.CrossRefGoogle Scholar
  12. 12.
    Levine AM, Sadeghi S, Espina B, Tulpule A, Nathwani B. Characteristics of indolent non-Hodgkin lymphoma in patients with type 1 human immunodeficiency virus infection. Cancer. 2002;94:1500–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Lowenthal DA, et al. AIDS-related lymphoid neoplasia. The Memorial Hospital experience. Cancer. 1988;61:2325–37.CrossRefPubMedGoogle Scholar
  14. 14.
    Ziegler JL, et al. Non-Hodgkin’s lymphoma in 90 homosexual men. Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome. N Engl J Med. 1984;311:565–70.CrossRefPubMedGoogle Scholar
  15. 15.
    Maurer C, Hallek M. Chronic lymphocytic leukemia. Dtsch Med Wochenschr (1946). 2013;138:2153–66.CrossRefGoogle Scholar
  16. 16.
    Ghia P, Caligaris-Cappio F. The origin of B-cell chronic lymphocytic leukemia. Semin Oncol. 2006;33:150–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Hallek M, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–56.PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Ravandi F, Verma A, Ridgeway J, Pursell K. Chronic lymphocytic leukemia (B-CLL) occurring with human immunodeficiency virus (HIV) infection: implications. Leuk Res. 2003;27:853–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Cole J, Pantanowitz L, Aboulafia D. Human immunodeficiency virus and chronic lymphocytic leukemia. Leuk Lymphoma. 2009;50:1885–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Sewell HF, Walker F, Bennett B, Dawson AA. Chronic lymphocytic leukaemia contemporaneous with HIV infection. Br Med J (Clin Res Ed). 1987;294:938–9.CrossRefGoogle Scholar
  21. 21.
    Shimada N, et al. Treatment of chronic lymphocytic leukemia with bendamustine in an HIV-infected patient on antiretroviral therapy: a case report and review of the literature. Clin Case Rep. 2015;3:453–60.PubMedCentralCrossRefPubMedGoogle Scholar
  22. 22.
    Knowles DM, et al. Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS). The New York University Medical Center experience with 105 patients (1981–1986). Ann Intern Med. 1988;108:744–53.CrossRefPubMedGoogle Scholar
  23. 23.
    Kaplan MH, et al. Neoplastic complications of HTLV-III infection. Lymphomas and solid tumors. Am J Med. 1987;82:389–96.CrossRefPubMedGoogle Scholar
  24. 24.
    Samji H, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013;8:e81355.PubMedCentralCrossRefPubMedGoogle Scholar
  25. 25.
    Callea V, et al. Incidence of second neoplasia in patients with B-cell chronic lymphocytic leukemia treated with chlorambucil maintenance chemotherapy. Leuk Lymphoma. 2006;47:2314–20.CrossRefPubMedGoogle Scholar
  26. 26.
    Tsimberidou AM, Wen S, McLauaghlin P, et al. Other malignancies in chronic lymphocyticleukemia/small lymphocytic lymphoma. J Clin Oncol. 2008;27:1–9.CrossRefGoogle Scholar
  27. 27.
    Gibson TM, Morton LM, Shiels MS, Clarke CA, Engels EA. Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study. AIDS (London, England). 2014;28:2313–8.CrossRefGoogle Scholar
  28. 28.
    Rossi D, et al. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med. 2012;209:1537–51.PubMedCentralCrossRefPubMedGoogle Scholar
  29. 29.
    Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol: Off J Am Soc Clin Oncol. 1998;16:2780–95.Google Scholar
  30. 30.
    Radaszkiewicz T, Dragosics B, Bauer P. Gastrointestinal malignant lymphomas of the mucosa-associated lymphoid tissue: factors relevant to prognosis. Gastroenterology. 1992;102:1628–38.PubMedGoogle Scholar
  31. 31.
    Parsonnet J, et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med. 1994;330:1267–71.CrossRefPubMedGoogle Scholar
  32. 32.
    Auer IA, et al. t(11;18)(q21;q21) is the most common translocation in MALT lymphomas. Ann Oncol: Off J Eur Soc Med Oncol ESMO. 1997;8:979–85.CrossRefGoogle Scholar
  33. 33.
    Zucca E, Bertoni F, Roggero E, Cavalli F. The gastric marginal zone B-cell lymphoma of MALT type. Blood. 2000;96:410–9.PubMedGoogle Scholar
  34. 34.
    Wotherspoon AC, et al. Low grade gastric B-cell lymphoma of mucosa associated lymphoid tissue in immunocompromised patients. Histopathology. 1996;28:129–34.CrossRefPubMedGoogle Scholar
  35. 35.
    Liu L, et al. Splenic marginal zone lymphoma: a population-based study on the 2001–2008 incidence and survival in the United States. Leuk Lymphoma. 2013;54:1380–6.CrossRefPubMedGoogle Scholar
  36. 36.
    Berger F, et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood. 2000;95:1950–6.PubMedGoogle Scholar
  37. 37.
    Clipson A, et al. KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype. Leukemia. 2015;29:1177–85.CrossRefPubMedGoogle Scholar
  38. 38.
    Zuckerman E, et al. Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma. Ann Intern Med. 1997;127:423–8.CrossRefPubMedGoogle Scholar
  39. 39.
    Cagliuso M, et al. Splenic marginal zone lymphoma in a HIV-1 infected patient: evidence favouring a pathogenetic role of HIV-1 itself in the lymphomagenesis. Infection. 2013;41:255–8.CrossRefPubMedGoogle Scholar
  40. 40.
    Genet P, et al. Splenic marginal zone lymphoma with villous lymphocytes in patients with human immunodeficiency virus. Leuk Lymphoma. 2013;54:181–3.CrossRefPubMedGoogle Scholar
  41. 41.
    Arcaini L, et al. Splenic marginal zone B-cell lymphoma in a HIV-positive patient: a case report. Ann Hematol. 2009;88:379–81.CrossRefPubMedGoogle Scholar
  42. 42.
    Conconi A, et al. Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes. Blood. 2001;98:781–6.CrossRefPubMedGoogle Scholar
  43. 43.
    Abella E, et al. Nodal marginal zone lymphoma in AIDS patients: a casual association? AIDS (London, England). 2002;16:2232–4.CrossRefGoogle Scholar
  44. 44.
    Charton-Bain MC, Le Tourneau A, Weiss L, Bruneval P, Diebold J. Rare non-Hodgkin’s lymphoma in the course of infection with human immunodeficiency virus. Two cases with bone marrow invasion. Ann Pathol. 1997;17:38–40.PubMedGoogle Scholar
  45. 45.
    Sheibani K, et al. Monocytoid B-cell lymphoma in a patient with human immunodeficiency virus infection. Demonstration of human immunodeficiency virus sequences in paraffin-embedded lymph node sections by polymerase chain reaction amplification. Arch Pathol Lab Med. 1990;114:1264–7.PubMedGoogle Scholar
  46. 46.
    A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood. 1997;89:3909–18.Google Scholar
  47. 47.
    Gertz MA, Fonseca R, Rajkumar SV. Waldenstrom’s macroglobulinemia. Oncologist. 2000;5:63–7.CrossRefPubMedGoogle Scholar
  48. 48.
    Treon SP, et al. MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. N Eng J Med. 2012;367:826–33.CrossRefGoogle Scholar
  49. 49.
    Koshiol J, Gridley G, Engels EA, McMaster ML, Landgren O. Chronic immune stimulation and subsequent Waldenstrom macroglobulinemia. Arch Intern Med. 2008;168:1903–9.PubMedCentralCrossRefPubMedGoogle Scholar
  50. 50.
    Terrier B, et al. Characteristics of B-cell lymphomas in HIV/HCV-coinfected patients during the combined antiretroviral therapy era: an ANRS CO16 LYMPHOVIR cohort study. J Acquir Immune Defic Syndr (1999). 2013;63:249–53.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Nadia Khan
    • 1
    Email author
  • Dipesh Uprety
    • 2
  • Jenny Seo
    • 3
  • Mark Leick
    • 4
  1. 1.Department of OncologyFox Chase Cancer Center, Temple University School of MedicinePhiladelphiaUSA
  2. 2.Department of Internal MedicineAbington Memorial Hospital, Abington Jefferson Health SystemAbingtonUSA
  3. 3.Department of Internal MedicinePhiladelphia College of Osteopathic Medicine (PCOM)PhiladelphiaUSA
  4. 4.Department of Internal MedicineJohns Hopkins Hospital, Johns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations